Angiotensin II and human obesity. A narrative review of the pathogenesis.
Angiotensina II y obesidad humana. Revisión narrativa de la patogénesis.
Palabras clave:
obesidad, angiotensina II, co-morbilidades, tejido adipose, inflamación
Resumen
La angiotensina II (Ang II) es una hormona y el principal efector del sistema renina-angiotensina (SRA). Este péptido tiene importantes efectos fisiopatológicos en la hipertensión, la hipertrofia cardíaca, la proliferación endotelial, la inflamación y la remodelación tisular a través de receptores acoplados a la proteína G. El papel pro-inflamatorio de la Ang II se ha reportado en diversos procesos inflamatorios. La obesidad está ligada a un proceso inflamatorio crónico que a su vez es causa de algunas de sus morbilidades. Se ha demostrado que la Ang II está relacionada con las comorbilidades de la obesidad, que incluyen alteraciones en el corazón, el riñón, la hipertensión y la coagulación. En este sentido, la activación de los receptores AT1 por la Ang II puede inducir un proceso inflamatorio mediado por el factor de transcripción NFkB desencadenado inflamación en diversos sistemas que se relacionan con las co-morbilidades observadas en la obesidad. El propósito de esta revisión fue destacar el efecto pro-inflamatorio de la Ang II y las alteraciones inducidas por esta hormona en diversos órganos y sistemas en la obesidad. La búsqueda se hizo desde 1990 a través de Medline, EMBASE and PubMed, utilizando las palabras clave: angiotensina II; angiotensina II, obesidad; angiotensina II, riñón, obesidad; angiotensina II, coagulación, obesidad; angiotensina II, inflamación, obesidad; angiotensin II, adipose tissue, obesidad; angiotensin II, hipertensión, obesidad; angiotensin II, resistencia a la insulina, obesidad; angiotensin II, adiponectina, leptina, obesidad; angiotensina II, COVID-19, obesidad. La angiotensina II a través de su interac- ción con su receptor AT1 puede inducir alteraciones en diversos sistemas que están relacionados con las comorbilidades observadas en la obesidad. Estrategias terapeúticas para disminuir su producción y la acción de la AngII pudieran mejorar las condiciones clínicas en individuos con obesidad.
Descargas
La descarga de datos todavía no está disponible.
Citas
Dandona P, Dhindsa S, Ghanim H, Chaudhuri A. Angiotensin II and inflammation: the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade. J Hum Hypertens 2007; 21:20-27. http://doi: 10.1038/sj.jhh.1002101.
Timmermans PB, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ, Lee R. J, Wexler RR, Saye JA, Smith RD. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993; 45: 205-251.
Ferrario CM, Chappell MC. Novel angiotensin peptides. Cell Mol Life Sci 2004; 61: 2720-2727. http://doi:10.1007/s00018-004-4243-4.
Crackower MA, Sarao R, Oudit GY, Yagil C, Kozieradzki I, Scanga SE, Oliveira- dos-Santos AJ, da Costa J, Zhang L, Pei Y, Scholey J, Ferrario CM, Manoukian AS, Chappell MC, Backx PH, Yagil Y, Penninger JM. Angiotensin converting enzyme 2 is an essential regulator of heart function. Nature 2002; 417: 822-828. http://doi: 10.1038/nature00786.
Reaux A, Fournie-Zaluski MC, Llorens-Cortes C. Angiotensin III: a central regulator of vasopressin release and blood pressure. Trends Endocrinol Metab 2001;12: 157-162. http://doi:10.1016/s1043-2760(01)00381-2.
Hunyady L, Catt KJ. Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II. Mol Endocrinol 2006; 20: 953-970. http://doi: 10.1210/me.2004-0536.
Watanabe Y, Nagai Y, Takatsu K. Activation and regulation of the pattern recognition receptors in obesity-induced adipose tissue inflammation and insulin resistance. Nutrients 2013; 5:3757–3778. http://dx.doi. org/10.3390/ nu5093757.
Ryder E, Pedreañez A, Vargas R, Peña C, Fernandez E, Diez-Ewald M, Mosquera J. Increased proinflammatory markers and lipoperoxidation in obese individuals: Inicial inflammatory events? Diabetes Metab Syndr 2015;9:280-286. http://doi: 10.1016/j. dsx.2014.04.022.
Vargas R, Ryder E, Diez-Ewald M, Mosquera J, Durán A, Valero N, Pedreañez A, Peña C, Fernández E. Increased Creactive protein and decreased Interleukin-2 content in serum from obese individuals with or without insulin resistance: Associations with leukocyte count and insulin and adiponectin content. Diabetes Metab Syndr 2016;10: S34-41. http://doi: 10.1016/j. dsx.2015.09.007.
Underwood PC, Adler GK. The renin angiotensin aldosterone system and insulin resistance in humans. Curr Hypertens Rep 2013; 15:59–70. http://dx.doi.org/10.1007/ s11906-012-0323-2.
Nakagami H, Morishita R. Obesity and gastrointestinal hormones-dual effect of angiotensin II receptor blockade and a partial agonist of PPAR-γ. Curr Vasc Pharmacol 2011;9:162-166. http://doi: 10.2174/157016111794519291.
de Kloet AD, Pioquinto DJ, Nguyen D, Wang L, Smith JA, Hiller H, Summer C. Obesity induces neuroinflammation mediated by altered expression of the renin-angiotensin system in mouse forebrain nuclei. Physiol Behav 2014; 136:31-38. http://doi: 10.1016/j.physbeh.2014.01.016.
Segura J, Ruilope LM. Obesity, essential hypertension and renin-angiotensin system. Public Health Nutr 2007; 10:1151-1155. http://doi: 10.1017/S136898000700064X.
Rüster C, Wolf G. The role of the renin-angiotensin-aldosterone system in obesity-related renal diseases. Semin Nephrol 2013; 33:44-53. http://doi: 10.1016/j.semnephrol.2012.12.002.
Long AN, Dagogo-Jack S. Comorbidities of diabetes and hypertension: mechanisms and approach to target organ protection. J Clin Hypertens (Greenwich) 2011;13:244- 251. http://doi: 10.1111/j.1751-7176.
2011.00434.x.
Zhou Y, Chi J, Lv W, Wang Y. Obesity and diabetes as high-risk factors for severe coronavirus disease 2019 (Covid-19). Diabetes Metab Res Rev 2021; 37:e3377. http://doi: 10.1002/dmrr.3377.
Mosquera-Sulbaran J, Pedreañez A, Carrero Y, Callejas D. C-reactive protein as an effector molecule in the COVID-19 pathogenesis. Rev Med Virol 2021; 1-8: e2221. https://doi.org/10.1002/rmv.2221.
Danilczyk U, Penninger JM. Angiotensin- converting enzyme II in the heart and the kidney. Circ Res 2006: 98: 463-471. http://doi: 10.1161/01.RES.0000205761.22353.5f.
Huang XR, Chen WY, Truong LD, Lan HY. Chymase is upregulated in diabetic nephropathy: implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease. J Am Soc Nephrol 2003;14: 1738-1747. http://doi: 10.1097/01.asn.0000071512.93927.4e.
Bacani C, Frishman WH. Chymase: a new pharmacologic target in cardiovascular disease. Cardiol Rev 2006; 14: 187-193. http:// doi:10.1097/01.crd.0000195220.62533.c5.
Cesari M, Rossi GP, Pessina AC. Biological properties of the angiotensin peptides other than angiotensin II: implications for hypertension and cardiovascular diseases. J Hypertens 2002; 20: 793-799. http://doi: 10.1097/00004872-200205000-00002.
Hamilton TA, Handa RK, Harding JW, Wright JW. A role for angiotensin IV/AT4 system in mediating natiuresis in the rat. Peptides 2001; 22: 935-944. http://doi: 10.1016/s0196-9781(01)00405-3.
Kramar EA, Harding JW, Wright JW. Angiotensin II- and IV-induced changes in cerebral blood flow. Roles of AT1 and AT2, and AT4 receptor subtypes. Regul Pept 1997; 68: 131-138. http://doi: 10.1016/s0167-0115(96)02116-7.
Van Kats JP, Danser AH, van Meegen JR, Sassen LM, Verdouw PD, Schalekamp MA. Angiotensin production by the heart: a quantitative study in pigs with the use of radiolabeled angiotensin infusion. Circulation 1998; 98: 73-81. http://doi:10.1161/01. cir.98.1.73.
Kobori H, Pieto-Carrasquero MC, Ozawa Y, Navar LG. AT1 receptor mediated augmentation of intrarenal angiotensinogen in angiotensin II dependent hypertension. Hypertension 2004; 43: 1126-1132. http://doi: 10.1161/01.HYP.0000122875.91100.28.
Moulik S, Speth RC, Turner BB, Rowe BP. Angiotensin II receptor subtype distribution in the rabbit brain. Exp Brain Res 2002; 142: 275-283. http://doi: 10.1007/ s00221-001-0940-5.
Ghiani BU, Masini MA. Angiotensin II bindings sites in the rat pancreas and their modulation after sodium loading and depletion. Comp Biochem Physiol A Physiol 1995; 111: 439-444. http://doi:10.1016/0300-9629(95)00030-b.
Karlsson C, Lindell K, Ottosson M, Sjostrom L, Carlsson B, Carlsso L. Human adipose tissue expresses angiotensinogen and enzymes required for its conversion to angiotensin II. J Clin Endocrinol Metabol 1998; 83: 3925-3929. http://doi:10.1210/ jcem.83.11.5276.
de Mello W. Effect of extracellular and intra-cellular angiotensin on heart cell function; on the cardiac renin-angiotensin system. Regul Pept 2003; 114: 87-90. http:// doi:10.1016/s0167-0115(03)00121-6.
Re RN, Cook JL. The intracrine hypothesis: an update. Regul Pept 2006;133: 1-9. http://doi:10.1016/j.regpep.2005.09.012.
Ruster C, Wolf G. Renin-angiotensin-aldos- terone system and progression of renal disease. J Am Soc Nephrol 2006; 17: 2985-2991. http://doi: 10.1681/ASN.2006040356.
Porrello ER, Delbridge LM, Thomas WG. The angiotensin II type 2 (AT2) receptor: an enigmatic seven transmembrane receptor. Front BioSci 2009;14: 958-972. http:// doi:10.2741/3289.
Ito N, Ohishi M, Yamamoto K, Tatara Y, Shiota A, Hayashi N, Komai N, Yanagitani Y, Rakugi H, Ogihara T. Renin- angiotensin inhibition reverses advanced cardiac remodeling in aging spontaneously hypertensive rats. Am J Hypertens 2007; 20: 792-799. http://doi: 10.1016/j.amjhy- per.2007.02.004.
Thekkumkara TJ, Cookson R, Linas SL. Angiotensin (AT1A) receptor mediated increases in transcellular sodium transport in proximal tubule cells. Am J Physiol 1998; 274: F897-F905. http://doi:10.1152/ ajprenal.1998.274.5.F897.
Aguilera G. Role of angiotensin II receptor subtypes on the regulation of aldosterone secretion in the adrenal glomerulosa zone in the rat. Mol Cell Endocrinol 1992; 90: 53-60. http://doi: 10.1016/0303-7207(92)90101-b.
Davisson RL, Oliverio MI, Coffman TM, Sigmund CD. Divergent functions of angiotensin II receptor isoforms in the brain. J Clin Invest 2000; 106: 103-106. http://doi: 10.1172/JCI10022.
Oliverio MI, Coffman TM. Angiotensin II receptor physiology using gene tar- geting. News Physiol Sci 2000; 15: 171- 175. http://doi 10.1152/physiologyonli- ne.2000.15.4.171.
Schulman IH, Raij L. The angiotensin II type 2 receptor: what is its clinical significance? Curr Hypertens Rep 2008; 10: 188-193. http:// doi: 10.1007/s11906-008-0036-8.
Esteban V, Lorenzo O, Ruperez M, Suzuki Y, Mezzano S, Blanco J, Kretzler M, Sugaya T, Egido, J, Ruiz-Ortega M. Angiotensin II, via AT1 and AT2 receptors and NF-kB pathway, regulates the inflammatory response in unilateral ureteral obstruction. J Am Soc Nephrol 2004; 15: 1514-1529. http://doi: 10.1097/01. asn.0000130564.75008.f5.
Ruiz-Ortega M, Esteban V, Suzuki Y, Ruperez M, Mezzano S, Ardiles L, Justo P, Ortiz A, Egido J. Renal expression of angiotensin type 2 (AT2) receptors during kidney damage. Kidney Int Suppl 2003; 86: S21-S26. http://doi: 10.1046/j.1523-1755.64.s86.5.x.
de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 2000; 52: 415-472.
Cornier MA, Dabelea D, Hernandez TL, Lindstrom RC, Steig AJ, Stob NR, Van Pelt RE, Wang H, Eckel RH. The metabolic syndrome. Endocr Rev 2008; 29:777–822. http://dx.doi.org/10.1210/er.2008-0024.
Reaven GM. The insulin resistance syndrome: definition and dietary approaches to treatment. Annu Rev Nutr 2005; 25:391–406. http://doi: 10.1146/annurev. nutr.24.012003.132155.
Osborn O, Olefsky JM. The cellular and signaling networks linking the immune system and metabolism in disease. Nat Med 2012; 18:363–374. http://dx.doi.org/10.1038/ nm.2627.
Romeo GR, Lee J, Shoelson SE. Metabolic syndrome, insulin resistance, and roles of inflammation – mechanisms and therapeutic targets. Arterioscler Thromb Vasc Biol 2012; 32:1771–1776. http://dx.doi. org/10.1161/ATVBAHA.111.241869.
Ryder E, Diez-Ewald M, Mosquera J, Fernández E, Pedreañez A, Vargas R, Peña C, Fernández N. Association of obesity with leukocyte count in obese individuals without metabolic syndrome. Diabetes Metab Syndr 2014;8:197-204. http://doi: 10.1016/j.dsx.2014.09.002.
Frohlich ED. Clinical management of the obese hypertensive patient. Cardiol Rev 2002; 10:127-138. http://doi: 10.1097/00045415-200205000-00001
Saint-Marc P, Kozak LP, Ailhaud G, Darimont C, Negrel R. Angiotensin II as a trophic factor of white adipose tissue: stimulation of adipose cell formation. Endocrinology 2001; 142:487–492. http://doi: 10.1210/endo.142.1.7883.
Dolgacheva LP, Turovskaya MV, Dynnik VV, Zinchenko VP, Goncharov NV, Davletov B, Turovsky EA. Angiotensin II activates different calcium signaling pathways in adipo-cytes. Arch Biochem Biophys 2016; 593:38-49. http://doi: 10.1016/j.abb.2016.02.001.
Palominos MM, Dünner DH, Wabitsch M, Rojas CV. 2015. Angiotensin II directly impairs adipogenic differentiation of human preadipose cells. Mol Cell Biochem 2015; 408: 115-122. http://doi: 10.1007/s11010-015-2487-y.
Schling MM, Dünner NH, Wabitsch M, Rojas CV. Angiotensin II directly impairs adipogenic differentiation of human preadipose cells. Mol Cell Biochem 2015; 408:115-122. http://doi: 10.1007/s11010-015-2487-y.
Brücher R, Cifuentes M, Acuña MJ, Albala C, Rojas CV. Larger anti-adipogenic effect of angiotensin II on omental preadipose cells of obese humans. Obesity 2007; 15:1643-1646. http://doi: 10.1038/oby.2007.196.
Fuentes P, Acuña MJ, Cifuentes M, Rojas CV. The anti-adipogenic effect of angiotensin II on human preadipose cells involves ERK1,2 activation and PPARG phosphorylation. J Endocrinol 2010; 206:75-83. http:// doi: 10.1677/JOE-10-0049.
Ye ZW, Wu XM, Jiang JG. Expression changes of angiotensin II pathways and bioactive mediators during human preadipocytes-visceral differentiation. Metabolism 2009; 58:1288-1296. http://doi: 10.1016/j.meta- bol.2009.04.014.
Jones BH, Standridge MK, Moustaid N. Angiotensin II increases lipogenesis in 3T3- L1 and human adipose cells. Endocrinology 1997; 138:1512-1519. http://doi: 10.1210/ endo.138.4.5038.
Townsend RR. The effects of angiotensin-II on lipolysis in humans. Metabolism 2001; 50:468-472. http://doi: 10.1053/ meta.2001.21021.
Weisinger RS, Begg DP, Jois M. Antagonists of the renin-angiotensin system and the prevention of obesity. Curr Opin Investig Drugs 2009; 10: 1069-1077.
Than A, Leow MK, Chen P. Control of adipo- genesis by the autocrine interplays between angiotensin 1-7/Mas receptor and angiotensin II/AT1 receptor signaling pathways. J Biol Chem 2013; 288:15520-15531. http://doi: 10.1074/jbc.M113.459792.
Sharma AM, Engeli S. The role of reninangiotensin system blockade in the management of hypertension associated with the cardiometabolic syndrome. J Cardiometab Syndr 2006; 1:29-35. http://doi: 10.1111/ j.0197-3118.2006.05422. x.
Marchesi C, Paradis P, Schiffrin EL. Role of the reninangiotensin system in vascular inflammation. Trends Pharmacol Sci 2008; 29: 367-374. http://doi: 10.1016/j. tips.2008.05.003.
Chua CC, Hamdy RC, Chua BH. Upregulation of vascular endothelial growth factor by angiotensin II in rat heart endothelial cells. Biochim Biophys Acta 1998; 1401: 187-194. http://doi: 10.1016/s0167-4889(97)00129-8.
Kitayama H, Maeshima Y, Takazawa Y, Yamamoto Y, Wu Y, Ichinose K, Hirokoshi K, Sugiyama H, Yamasaki Y, Makino H. Regulation of angiogenic factors in angiotensin II infusion model in association with tubulointerstitial injuries. Am J Hypertens 2006; 19: 718-727. http://doi: 10.1016/j. amjhyper.2005.09.022.
Suzuki Y, Ruiz-Ortega M, Lorenzo O, Ruperez M, Esteban V, Egido J. Inflammation and angiotensin II. Int J Biochem Cell Biol 2003;35: 881-900. http://doi: 10.1016/ s1357-2725(02)00271-6.
Alvarez A, Cerda´-Nicola´s M, Abu N, Nabah Y, Mata M, Issekutz AC, Panés J, Lobb RR, Sanz MJ. Direct evidence of leukocyte adhesion in arterioles by angiotensin II. Blood 2004; 104: 402-408. http://doi: 10.1182/blood-2003-08-2974.
Piqueras L, Kubes P, Alvarez A, O’Connor E, Issekutz AC, Esplugues JV, Sanz MJ. Angiotensin II induces leukocyte- endothelial cell interactions in vivo via AT(1) and AT(2) receptor-mediated P- selectin upregulation. Circulation 2000; 102: 2118-2123. http://doi: 10.1161/01. cir.102.17.2118.
Pueyo ME, Gonzalez W, Nicoletti A, Savoie F, Arnal JF, Michel JB. Angiotensin stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-kappaB activation induced by intracellular oxidative stress. Artherocler
Thromb Vasc Biol 2000; 20: 645-651. http://doi: 10.1161/01. atv.20.3.645.
Crowley SD, Frey CW, Gould SK, Griffiths R, Ruiz P, Burchette JL, Howell DN, Makhanova N, Yan M, Kim HS, Tharaux PL, Coffman TM. Stimulation of lymphocyte responses by angiotensin II promotes kidney injury in hypertension. Am J Physiol Renal Physiol 2008;295: F515-F524. http:// doi: 10.1152/ajprenal.00527.2007.
Jurewicz M, McDermott DH, Sechler JM, Tinckam K, Takakura A, Carpenter CB, Milford E, Abdi R. Human T and natural killer cells possess a functional renin-an- giotensin system: further mechanisms of angiotensin II induced inflammation. J Am Soc Nephrol 2007;18: 1093-10102. http:// doi: 10.1681/ASN.2006070707.
Kvakan H, Kleinewietfeld M, Qadri F, Park JK, Fischer R, Schwarz I, Rahn HP, Plehm R, Wellner M, Elitok S, Gratze P, R, Luft FC, Muller DN. Regulatory T cells ameliorate angiotensin II-induced cardiac damage. Circulation 2009;119: 2904- 2912. http://doi: 10.1161/CIRCULATIO- NAHA.108.832782.
Welch WJ. Angiotensin II-dependent superoxide: effects on hypertension and vascular dysfunction. Hypertension 2008;52: 51-56. http://doi: 10.1161/HYPERTENSIONA- HA.107.090472.
Wu R, Laplante MA, de Champlain J. Cyclooxygenase-2 inhibitors attenuate angiotensin II-induced oxidative stress, hypertension, and cardiac hypertrophy in rats. Hypertension 2005; 45: 1139-1144. http://doi: 10.1161/01. HYP.0000164572.92049.29.
Wen Y, Liu Y, Tang T, Lv L, Liu H, Ma K, Liu B. NLRP3 inflammasome activation is involved in Ang II-induced kidney damage via mitochondrial dysfunction. Onco- target 2016;7:54290-54302. http://doi: 10.18632/oncotarget.11091.
Thakur S, Li L, Gupta S. NF-κB-mediated integrin-linked kinase regulation in angiotensin II-induced pro-fibrotic process in cardiac fibroblasts. Life Sci 2014;107:68- 75. http://doi: 10.1016/j.lfs.2014.04.030.
Weber KT, Swamynathan SK, Guntaka RV, Sun Y. Angiotensin II and extracellular matrix homeostasis. J Biochem Cell Biol 1999;31:395-403. http://doi: 10.1016/ s1357-2725(98)00125-3.
Weisinger RS, Begg DP, Chen N, Jois M, Mathai ML, Sinclair AJ. The problem of obesity: is there a role for antagonists of the renin-angiotensin system? Asia Pac J Clin Nutr 2007; 16:359-367.
Maeda A, Tamura K, Wakui H, Dejima T, Ohsawa M, Azushima K, Kanaoka T, Uneda K, Matsuda M, Yamashita A, Miyazak, NK, Hirawa N, Toya Y, Umemura S. Angiotensin receptor-binding protein ATRAP/ Agtrap inhibits metabolic dysfunction with visceral obesity. J Am Heart Assoc 2013;2: e000312. http://doi: 10.1161/ JAHA.113.000312.
Xue B, Thunhorst RL, Yu Y, Guo F, Beltz TG, Felder RB, Johnson AK. Central renin-angiotensin system activation and inflammation induced by high-fat diet sensitize angiotensin II-elicited hypertension. Hypertension. 2016; 67:163-170. http://doi: 10.1161/HYPERTENSIONAHA.115.06263.
Tsuchiya K, Yoshimoto T, Hirono Y, Tateno Tama T, Hirata Y. Angiotensin II induces monocyte chemoattractant protein-1 expression via a nuclear factor-kappaB- dependent pathway in rat preadipocytes. Am J Physiol Endocrinol Metab 2006;291: E771-778. http://doi: 10.1152/ajpen- do.00560.2005.
Menikdiwela KR, Ramalingam L, Allen L, Scoggin S, Kalupahana NS, Moustaid- Moussa N. Angiotensin II increases endoplasmic reticulum stress in adipose tissue and adipocytes. Sci Rep 2019; 9:8481. http://doi: 10.1038/s41598-019-44834-8.
Zhang JX, Lin X, Xu J, Tang F. Hyperuricemia inhibition protects SD rats against fructose-induced obesity hypertension via modulation of inflammation and renin-an-giotensin system in adipose tissue. Exp Clin Endocrinol Diabetes 2021; 129:314-321. http://doi:10.1055/a-1023-6710.
Hussain T. Renal angiotensin II receptors, hyperinsulinemia, and obesity. Clin Exp Hypertens 2003; 25:395-403. http://doi: 10.1081/ceh-120024983.
Chalmers L, Kaskel FJ, Bamgbola O. The role of obesity and its bioclinical correlates in the progression of chronic kidney disease. Adv Chronic Kidney Dis 2006; 13:352-364. http://doi: 10.1053/j. ackd.2006.07.010.
Gao N, Wang H, Zhang X, Yang Z. The inhibitory effect of angiotensin II on BKCa channels in podocytes via oxidative stress. Mol Cell Biochem 2015;398:217-222. http://doi: 10.1007/s11010-014-2221-1.
Saginova EA, Fedorova EIu, Fomin VV, Moiseev SV, Minakova EG, Gitel’ EP, Samokhodskaia LM, Kutyrina IM, Mukhin NA. [Development of renal affection in obese patients]. Ter Arkh 2006; 78:36-41.
Stepp DW, Boesen EI, Sullivan JC, Mintz JD, Hair CD, Pollock DM. Obesity augments vasoconstrictor reactivity to angiotensin II in the renal circulation of the Zucker rat. Am J Physiol Heart Circ Physiol 2007 ;293:H2537-542. http://doi: 10.1152/ajpheart.01081.2006.
Hongo M, Ishizaka N, Furuta K, Yahagi N, Saito K, Sakurai R, Matsuzaki G. Koike K, Nagai R. Administration of angiotensin II, but not catecholamines, induces accumulation of lipids in the rat heart. Eur J Pharmacol 2009; 604:87-92. http://doi: 10.1016/j.ejphar.2008.12.006.
Mayor F Jr, Cruces-Sande M, Arcones AC, Vila-Bedmar R, Briones AM, Salaices M, Murga C. G protein-coupled receptor kinase 2 (GRK2) as an integrative signalling node in the regulation of cardiovascular function and metabolic homeostasis. Cell Signal 2018; 41:25-32. http://doi: 10.1016/j.cellsig.2017.04.002.
Glenn DJ, Cardema MC, Ni W, Zhang Y, Yeghiazarians Y, Grapov D, Fiehn O, Gardner DG. Cardiac steatosis potentiates angiotensin II effects in the heart. Am J Physiol Heart Circ Physiol 2015;308:H339-350. http://doi:10.1152/ajpheart.00742.2014.
Sarzani R, Salvi F, Dessì-Fulgheri P, Rappelli A. Renin-angiotensin system, natriuretic peptides, obesity, metabolic syndrome, and hypertension: an integrated view in humans. J Hypertens 2008; 26:831-843. http://doi: 10.1097/ HJH.0b013e3282f624a0.
du Toit EF, Nabben M, Lochner A. A potential role for angiotensin II in obesity induced cardiac hypertrophy and ischaemic/ reperfusion injury. Basic Res Cardio 2005; 100:346-354. http://doi: 10.1007/s00395-005-0528-5.
Kintscher U, Lyon CJ, Law RE. Angiotensin II, PPAR-gamma and atherosclerosis. Front Biosci 2004; 9:359-369. http://doi: 10.2741/1225.
Schuchard J, Winkler M, Stölting I, Schuster F, Vogt FM, Barkhausen J, Thorns C, Santos RA, Bader M, Raasch W. Lack of weight gain after angiotensin AT1 receptor blockade in diet-induced obesity is partly mediated by an angiotensin-(1-7)/ Mas-dependent pathway. Br J Pharmacol 2015; 172:3764-3778. http://doi: 10.1111/ bph.13172.
Kochueva M, Sukhonos V, Shalimova A, Psareva V, Kirichenko N. State of integral remodeling parameters of target organs in patients with essential hypertension and obesity. Georgian Med News 2014;231:26-30.
South AM, Nixon PA, Chappell MC, Diz DI, Russell GB, Shaltout HA, O’Shea MT, Washburn LK. Obesity is associated with higher blood pressure and higher levels of angiotensin II but lower angiotensin-(1-7) in adolescents born preterm. J Pediatr 2019; 205:55-60. http://doi: 10.1016/j. jpeds.2018.09.058.
Xue B, Yu Y, Zhang Z, Guo F, Beltz TG, Thunhorst RL, Felder RB, Johnson AK. Leptin mediates high-fat diet sensitization of angiotensin II-elicited hypertension by upregulating the brain renin-angiotensin system and inflammation. Hypertension 2016; 67:970-976. http://doi: 10.1161/HY- PERTENSIONAHA.115.06736.
Deji N, Kume S, Araki S, Isshiki K, Araki H, Chin-Kanasaki M, Tanaka Y, Nishiyama A, Koya D, Haneda M, Kashiwagi A, Maegawa H, Uzu T. Role of angiotensin II-mediated AMPK inactivation on obesity-related salt-sensitive hypertension. Biochem Biophys Res Commun 2012; 418:559-564. http://doi:10.1016/j. bbrc.2012.01.070.
Asferg CL, Nielsen SJ, Andersen UB, Linneberg A, Møller DV, Hedley PL, Christiansen M, Goetze JP, Esler M, Jeppesen JL. Relative atrial natriuretic peptide deficiency and inadequate renin and angiotensin II suppression in obese hypertensive men. Hypertension 2013; 62:147-153. http://doi: 10.1161/HYPERTENSIONA-HA.111.00791.
Vaidya A, Forman JP, Williams JS. Vitamin D and the vascular sensitivity to angiotensin II in obese Caucasians with hypertension. J Hum Hypertens 2011; 25:672-678. http://doi: 10.1038/jhh.2010.110.
Lebovitz HE. Insulin resistance: definition and consequences. Exp Clin Endocrinol Diabetes 2001;109:S135-148. http://doi: 10.1055/s-2001-18576.
Olivares-Reyes JA, Arellano-Plancarte A, Castillo-Hernandez JR. Angiotensin II and the development of insulin resistance: implications for diabetes. Mol Cell Endocrinol 2009; 302:128-139. http://doi: 10.1016/j. mce.2008.12.011.
Ohki K, Wakui H, Kishio N, Azushima K, Uneda K , Haku S, Kobayashi R, Haruhara K, Kinguchi S, Yamaji T, Yamada T, Minegishi S, Ishigami T, Toya Y, Yamashita A, Imajo K, Nakajima A, Kato I, Ohashi K, Tamura K. Angiotensin II Type 1 receptor- associated protein inhibits angiotensin II- induced insulin resistance with suppression of oxidative stress in skeletal muscle tissue. Sci Rep 2018; 8:2846. http://doi: 10.1038/ s41598-018-21270-8.
Gao M, Du Y, Xie JW, Xue J, Wang YT, Qin L, Ma MM, Tang YB, Li XY. Redox signal-mediated TRPM2 promotes Ang II- induced adipocyte insulin resistance via Ca 2+-dependent CaMKII/JNK cascade. Metabolism 2018; 85:313-324. http://doi: 10.1016/j.metabol.2018.05.005.
Fuke Y, Fujita T, Satomura A, Wada Y, Matsumoto K. Alterations of insulin resistance and the serum adiponectin level in patients with Type 2 diabetes mellitus under the usual antihypertensive dosage of telmisartan treatment. Diabetes Technol Ther 2010; 12:393-398. http://doi: 10.1089/ dia.2009.0126.
López-Jaramillo P, Gómez-Arbeláez D, López-López J, López-López C, Martínez-Ortega J, Gómez-Rodríguez A, Martínez-Ortega J, Gómez-Rodríguez A, Triana-Cubillos S. The role of leptin/ adiponectin ratio in metabolic syndrome and diabetes. Horm Mol Biol Clin Inves- tig 2014; 18:37-45. http://doi: 10.1515/ hmbci-2013-0053.
Skurk T, van Harmelen V, Blum WF, Hauner H. Angiotensin II promotes leptin production in cultured human fat cells by an ERK1/2-dependent pathway. Obes Res 2005; 13:969-973. http://doi: 10.1038/ oby.2005.113.
Fortuño A, Rodríguez A, Gómez-Ambrosi J, Muñiz P, Salvador J, Díez J, Frühbeck G. Leptin inhibits angiotensin II-induced intracellular calcium increase and vaso-constriction in the rat aorta. Endocrinology 2002; 143:3555-3560. http://doi: 10.1210/ en.2002-220075.
Suzuki H, Eguchi S. Adiponectin versus angiotensin II: Key pathological role of their misbalance. Kidney Int 2006; 70:1678- 1679. http://doi: 10.1038/sj.ki.5001936.
Matsuzawa Y, Funahashi T, Kihara S, Shimomura I. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 2004; 24: 29–33. http://doi: 10.1161/01. ATV.0000099786.99623.EF.
Furuhashi M, Ura N, Higashiura K, Mu- rakami H, Tanaka M, Moniwa N, Yosida D, Shimamoto K. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 2003; 42: 76–81. http://doi: 10.1161/01. HYP.0000078490.59735.6E.
Christou GA, Kiortsis DN. The role of adiponectin in renal physiology and development of albuminuria. J Endocrinol 2014;221: R49-61. http://doi: 10.1530/ JOE-13-0578.
Mutch NJ, Wilson HM, Booth NA. Plasminogen activator inhibitor-1 and haemostasis in obesity. Proc Nutr Soc 2001;6:341- 347. http://doi: 10.1079/pns200199.
Skurk T, Lee YM, Hauner H. Angiotensin II and its metabolites stimulate PAI-1 protein release from human adipocytes in primary
Timmermans PB, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ, Lee R. J, Wexler RR, Saye JA, Smith RD. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993; 45: 205-251.
Ferrario CM, Chappell MC. Novel angiotensin peptides. Cell Mol Life Sci 2004; 61: 2720-2727. http://doi:10.1007/s00018-004-4243-4.
Crackower MA, Sarao R, Oudit GY, Yagil C, Kozieradzki I, Scanga SE, Oliveira- dos-Santos AJ, da Costa J, Zhang L, Pei Y, Scholey J, Ferrario CM, Manoukian AS, Chappell MC, Backx PH, Yagil Y, Penninger JM. Angiotensin converting enzyme 2 is an essential regulator of heart function. Nature 2002; 417: 822-828. http://doi: 10.1038/nature00786.
Reaux A, Fournie-Zaluski MC, Llorens-Cortes C. Angiotensin III: a central regulator of vasopressin release and blood pressure. Trends Endocrinol Metab 2001;12: 157-162. http://doi:10.1016/s1043-2760(01)00381-2.
Hunyady L, Catt KJ. Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II. Mol Endocrinol 2006; 20: 953-970. http://doi: 10.1210/me.2004-0536.
Watanabe Y, Nagai Y, Takatsu K. Activation and regulation of the pattern recognition receptors in obesity-induced adipose tissue inflammation and insulin resistance. Nutrients 2013; 5:3757–3778. http://dx.doi. org/10.3390/ nu5093757.
Ryder E, Pedreañez A, Vargas R, Peña C, Fernandez E, Diez-Ewald M, Mosquera J. Increased proinflammatory markers and lipoperoxidation in obese individuals: Inicial inflammatory events? Diabetes Metab Syndr 2015;9:280-286. http://doi: 10.1016/j. dsx.2014.04.022.
Vargas R, Ryder E, Diez-Ewald M, Mosquera J, Durán A, Valero N, Pedreañez A, Peña C, Fernández E. Increased Creactive protein and decreased Interleukin-2 content in serum from obese individuals with or without insulin resistance: Associations with leukocyte count and insulin and adiponectin content. Diabetes Metab Syndr 2016;10: S34-41. http://doi: 10.1016/j. dsx.2015.09.007.
Underwood PC, Adler GK. The renin angiotensin aldosterone system and insulin resistance in humans. Curr Hypertens Rep 2013; 15:59–70. http://dx.doi.org/10.1007/ s11906-012-0323-2.
Nakagami H, Morishita R. Obesity and gastrointestinal hormones-dual effect of angiotensin II receptor blockade and a partial agonist of PPAR-γ. Curr Vasc Pharmacol 2011;9:162-166. http://doi: 10.2174/157016111794519291.
de Kloet AD, Pioquinto DJ, Nguyen D, Wang L, Smith JA, Hiller H, Summer C. Obesity induces neuroinflammation mediated by altered expression of the renin-angiotensin system in mouse forebrain nuclei. Physiol Behav 2014; 136:31-38. http://doi: 10.1016/j.physbeh.2014.01.016.
Segura J, Ruilope LM. Obesity, essential hypertension and renin-angiotensin system. Public Health Nutr 2007; 10:1151-1155. http://doi: 10.1017/S136898000700064X.
Rüster C, Wolf G. The role of the renin-angiotensin-aldosterone system in obesity-related renal diseases. Semin Nephrol 2013; 33:44-53. http://doi: 10.1016/j.semnephrol.2012.12.002.
Long AN, Dagogo-Jack S. Comorbidities of diabetes and hypertension: mechanisms and approach to target organ protection. J Clin Hypertens (Greenwich) 2011;13:244- 251. http://doi: 10.1111/j.1751-7176.
2011.00434.x.
Zhou Y, Chi J, Lv W, Wang Y. Obesity and diabetes as high-risk factors for severe coronavirus disease 2019 (Covid-19). Diabetes Metab Res Rev 2021; 37:e3377. http://doi: 10.1002/dmrr.3377.
Mosquera-Sulbaran J, Pedreañez A, Carrero Y, Callejas D. C-reactive protein as an effector molecule in the COVID-19 pathogenesis. Rev Med Virol 2021; 1-8: e2221. https://doi.org/10.1002/rmv.2221.
Danilczyk U, Penninger JM. Angiotensin- converting enzyme II in the heart and the kidney. Circ Res 2006: 98: 463-471. http://doi: 10.1161/01.RES.0000205761.22353.5f.
Huang XR, Chen WY, Truong LD, Lan HY. Chymase is upregulated in diabetic nephropathy: implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease. J Am Soc Nephrol 2003;14: 1738-1747. http://doi: 10.1097/01.asn.0000071512.93927.4e.
Bacani C, Frishman WH. Chymase: a new pharmacologic target in cardiovascular disease. Cardiol Rev 2006; 14: 187-193. http:// doi:10.1097/01.crd.0000195220.62533.c5.
Cesari M, Rossi GP, Pessina AC. Biological properties of the angiotensin peptides other than angiotensin II: implications for hypertension and cardiovascular diseases. J Hypertens 2002; 20: 793-799. http://doi: 10.1097/00004872-200205000-00002.
Hamilton TA, Handa RK, Harding JW, Wright JW. A role for angiotensin IV/AT4 system in mediating natiuresis in the rat. Peptides 2001; 22: 935-944. http://doi: 10.1016/s0196-9781(01)00405-3.
Kramar EA, Harding JW, Wright JW. Angiotensin II- and IV-induced changes in cerebral blood flow. Roles of AT1 and AT2, and AT4 receptor subtypes. Regul Pept 1997; 68: 131-138. http://doi: 10.1016/s0167-0115(96)02116-7.
Van Kats JP, Danser AH, van Meegen JR, Sassen LM, Verdouw PD, Schalekamp MA. Angiotensin production by the heart: a quantitative study in pigs with the use of radiolabeled angiotensin infusion. Circulation 1998; 98: 73-81. http://doi:10.1161/01. cir.98.1.73.
Kobori H, Pieto-Carrasquero MC, Ozawa Y, Navar LG. AT1 receptor mediated augmentation of intrarenal angiotensinogen in angiotensin II dependent hypertension. Hypertension 2004; 43: 1126-1132. http://doi: 10.1161/01.HYP.0000122875.91100.28.
Moulik S, Speth RC, Turner BB, Rowe BP. Angiotensin II receptor subtype distribution in the rabbit brain. Exp Brain Res 2002; 142: 275-283. http://doi: 10.1007/ s00221-001-0940-5.
Ghiani BU, Masini MA. Angiotensin II bindings sites in the rat pancreas and their modulation after sodium loading and depletion. Comp Biochem Physiol A Physiol 1995; 111: 439-444. http://doi:10.1016/0300-9629(95)00030-b.
Karlsson C, Lindell K, Ottosson M, Sjostrom L, Carlsson B, Carlsso L. Human adipose tissue expresses angiotensinogen and enzymes required for its conversion to angiotensin II. J Clin Endocrinol Metabol 1998; 83: 3925-3929. http://doi:10.1210/ jcem.83.11.5276.
de Mello W. Effect of extracellular and intra-cellular angiotensin on heart cell function; on the cardiac renin-angiotensin system. Regul Pept 2003; 114: 87-90. http:// doi:10.1016/s0167-0115(03)00121-6.
Re RN, Cook JL. The intracrine hypothesis: an update. Regul Pept 2006;133: 1-9. http://doi:10.1016/j.regpep.2005.09.012.
Ruster C, Wolf G. Renin-angiotensin-aldos- terone system and progression of renal disease. J Am Soc Nephrol 2006; 17: 2985-2991. http://doi: 10.1681/ASN.2006040356.
Porrello ER, Delbridge LM, Thomas WG. The angiotensin II type 2 (AT2) receptor: an enigmatic seven transmembrane receptor. Front BioSci 2009;14: 958-972. http:// doi:10.2741/3289.
Ito N, Ohishi M, Yamamoto K, Tatara Y, Shiota A, Hayashi N, Komai N, Yanagitani Y, Rakugi H, Ogihara T. Renin- angiotensin inhibition reverses advanced cardiac remodeling in aging spontaneously hypertensive rats. Am J Hypertens 2007; 20: 792-799. http://doi: 10.1016/j.amjhy- per.2007.02.004.
Thekkumkara TJ, Cookson R, Linas SL. Angiotensin (AT1A) receptor mediated increases in transcellular sodium transport in proximal tubule cells. Am J Physiol 1998; 274: F897-F905. http://doi:10.1152/ ajprenal.1998.274.5.F897.
Aguilera G. Role of angiotensin II receptor subtypes on the regulation of aldosterone secretion in the adrenal glomerulosa zone in the rat. Mol Cell Endocrinol 1992; 90: 53-60. http://doi: 10.1016/0303-7207(92)90101-b.
Davisson RL, Oliverio MI, Coffman TM, Sigmund CD. Divergent functions of angiotensin II receptor isoforms in the brain. J Clin Invest 2000; 106: 103-106. http://doi: 10.1172/JCI10022.
Oliverio MI, Coffman TM. Angiotensin II receptor physiology using gene tar- geting. News Physiol Sci 2000; 15: 171- 175. http://doi 10.1152/physiologyonli- ne.2000.15.4.171.
Schulman IH, Raij L. The angiotensin II type 2 receptor: what is its clinical significance? Curr Hypertens Rep 2008; 10: 188-193. http:// doi: 10.1007/s11906-008-0036-8.
Esteban V, Lorenzo O, Ruperez M, Suzuki Y, Mezzano S, Blanco J, Kretzler M, Sugaya T, Egido, J, Ruiz-Ortega M. Angiotensin II, via AT1 and AT2 receptors and NF-kB pathway, regulates the inflammatory response in unilateral ureteral obstruction. J Am Soc Nephrol 2004; 15: 1514-1529. http://doi: 10.1097/01. asn.0000130564.75008.f5.
Ruiz-Ortega M, Esteban V, Suzuki Y, Ruperez M, Mezzano S, Ardiles L, Justo P, Ortiz A, Egido J. Renal expression of angiotensin type 2 (AT2) receptors during kidney damage. Kidney Int Suppl 2003; 86: S21-S26. http://doi: 10.1046/j.1523-1755.64.s86.5.x.
de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 2000; 52: 415-472.
Cornier MA, Dabelea D, Hernandez TL, Lindstrom RC, Steig AJ, Stob NR, Van Pelt RE, Wang H, Eckel RH. The metabolic syndrome. Endocr Rev 2008; 29:777–822. http://dx.doi.org/10.1210/er.2008-0024.
Reaven GM. The insulin resistance syndrome: definition and dietary approaches to treatment. Annu Rev Nutr 2005; 25:391–406. http://doi: 10.1146/annurev. nutr.24.012003.132155.
Osborn O, Olefsky JM. The cellular and signaling networks linking the immune system and metabolism in disease. Nat Med 2012; 18:363–374. http://dx.doi.org/10.1038/ nm.2627.
Romeo GR, Lee J, Shoelson SE. Metabolic syndrome, insulin resistance, and roles of inflammation – mechanisms and therapeutic targets. Arterioscler Thromb Vasc Biol 2012; 32:1771–1776. http://dx.doi. org/10.1161/ATVBAHA.111.241869.
Ryder E, Diez-Ewald M, Mosquera J, Fernández E, Pedreañez A, Vargas R, Peña C, Fernández N. Association of obesity with leukocyte count in obese individuals without metabolic syndrome. Diabetes Metab Syndr 2014;8:197-204. http://doi: 10.1016/j.dsx.2014.09.002.
Frohlich ED. Clinical management of the obese hypertensive patient. Cardiol Rev 2002; 10:127-138. http://doi: 10.1097/00045415-200205000-00001
Saint-Marc P, Kozak LP, Ailhaud G, Darimont C, Negrel R. Angiotensin II as a trophic factor of white adipose tissue: stimulation of adipose cell formation. Endocrinology 2001; 142:487–492. http://doi: 10.1210/endo.142.1.7883.
Dolgacheva LP, Turovskaya MV, Dynnik VV, Zinchenko VP, Goncharov NV, Davletov B, Turovsky EA. Angiotensin II activates different calcium signaling pathways in adipo-cytes. Arch Biochem Biophys 2016; 593:38-49. http://doi: 10.1016/j.abb.2016.02.001.
Palominos MM, Dünner DH, Wabitsch M, Rojas CV. 2015. Angiotensin II directly impairs adipogenic differentiation of human preadipose cells. Mol Cell Biochem 2015; 408: 115-122. http://doi: 10.1007/s11010-015-2487-y.
Schling MM, Dünner NH, Wabitsch M, Rojas CV. Angiotensin II directly impairs adipogenic differentiation of human preadipose cells. Mol Cell Biochem 2015; 408:115-122. http://doi: 10.1007/s11010-015-2487-y.
Brücher R, Cifuentes M, Acuña MJ, Albala C, Rojas CV. Larger anti-adipogenic effect of angiotensin II on omental preadipose cells of obese humans. Obesity 2007; 15:1643-1646. http://doi: 10.1038/oby.2007.196.
Fuentes P, Acuña MJ, Cifuentes M, Rojas CV. The anti-adipogenic effect of angiotensin II on human preadipose cells involves ERK1,2 activation and PPARG phosphorylation. J Endocrinol 2010; 206:75-83. http:// doi: 10.1677/JOE-10-0049.
Ye ZW, Wu XM, Jiang JG. Expression changes of angiotensin II pathways and bioactive mediators during human preadipocytes-visceral differentiation. Metabolism 2009; 58:1288-1296. http://doi: 10.1016/j.meta- bol.2009.04.014.
Jones BH, Standridge MK, Moustaid N. Angiotensin II increases lipogenesis in 3T3- L1 and human adipose cells. Endocrinology 1997; 138:1512-1519. http://doi: 10.1210/ endo.138.4.5038.
Townsend RR. The effects of angiotensin-II on lipolysis in humans. Metabolism 2001; 50:468-472. http://doi: 10.1053/ meta.2001.21021.
Weisinger RS, Begg DP, Jois M. Antagonists of the renin-angiotensin system and the prevention of obesity. Curr Opin Investig Drugs 2009; 10: 1069-1077.
Than A, Leow MK, Chen P. Control of adipo- genesis by the autocrine interplays between angiotensin 1-7/Mas receptor and angiotensin II/AT1 receptor signaling pathways. J Biol Chem 2013; 288:15520-15531. http://doi: 10.1074/jbc.M113.459792.
Sharma AM, Engeli S. The role of reninangiotensin system blockade in the management of hypertension associated with the cardiometabolic syndrome. J Cardiometab Syndr 2006; 1:29-35. http://doi: 10.1111/ j.0197-3118.2006.05422. x.
Marchesi C, Paradis P, Schiffrin EL. Role of the reninangiotensin system in vascular inflammation. Trends Pharmacol Sci 2008; 29: 367-374. http://doi: 10.1016/j. tips.2008.05.003.
Chua CC, Hamdy RC, Chua BH. Upregulation of vascular endothelial growth factor by angiotensin II in rat heart endothelial cells. Biochim Biophys Acta 1998; 1401: 187-194. http://doi: 10.1016/s0167-4889(97)00129-8.
Kitayama H, Maeshima Y, Takazawa Y, Yamamoto Y, Wu Y, Ichinose K, Hirokoshi K, Sugiyama H, Yamasaki Y, Makino H. Regulation of angiogenic factors in angiotensin II infusion model in association with tubulointerstitial injuries. Am J Hypertens 2006; 19: 718-727. http://doi: 10.1016/j. amjhyper.2005.09.022.
Suzuki Y, Ruiz-Ortega M, Lorenzo O, Ruperez M, Esteban V, Egido J. Inflammation and angiotensin II. Int J Biochem Cell Biol 2003;35: 881-900. http://doi: 10.1016/ s1357-2725(02)00271-6.
Alvarez A, Cerda´-Nicola´s M, Abu N, Nabah Y, Mata M, Issekutz AC, Panés J, Lobb RR, Sanz MJ. Direct evidence of leukocyte adhesion in arterioles by angiotensin II. Blood 2004; 104: 402-408. http://doi: 10.1182/blood-2003-08-2974.
Piqueras L, Kubes P, Alvarez A, O’Connor E, Issekutz AC, Esplugues JV, Sanz MJ. Angiotensin II induces leukocyte- endothelial cell interactions in vivo via AT(1) and AT(2) receptor-mediated P- selectin upregulation. Circulation 2000; 102: 2118-2123. http://doi: 10.1161/01. cir.102.17.2118.
Pueyo ME, Gonzalez W, Nicoletti A, Savoie F, Arnal JF, Michel JB. Angiotensin stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-kappaB activation induced by intracellular oxidative stress. Artherocler
Thromb Vasc Biol 2000; 20: 645-651. http://doi: 10.1161/01. atv.20.3.645.
Crowley SD, Frey CW, Gould SK, Griffiths R, Ruiz P, Burchette JL, Howell DN, Makhanova N, Yan M, Kim HS, Tharaux PL, Coffman TM. Stimulation of lymphocyte responses by angiotensin II promotes kidney injury in hypertension. Am J Physiol Renal Physiol 2008;295: F515-F524. http:// doi: 10.1152/ajprenal.00527.2007.
Jurewicz M, McDermott DH, Sechler JM, Tinckam K, Takakura A, Carpenter CB, Milford E, Abdi R. Human T and natural killer cells possess a functional renin-an- giotensin system: further mechanisms of angiotensin II induced inflammation. J Am Soc Nephrol 2007;18: 1093-10102. http:// doi: 10.1681/ASN.2006070707.
Kvakan H, Kleinewietfeld M, Qadri F, Park JK, Fischer R, Schwarz I, Rahn HP, Plehm R, Wellner M, Elitok S, Gratze P, R, Luft FC, Muller DN. Regulatory T cells ameliorate angiotensin II-induced cardiac damage. Circulation 2009;119: 2904- 2912. http://doi: 10.1161/CIRCULATIO- NAHA.108.832782.
Welch WJ. Angiotensin II-dependent superoxide: effects on hypertension and vascular dysfunction. Hypertension 2008;52: 51-56. http://doi: 10.1161/HYPERTENSIONA- HA.107.090472.
Wu R, Laplante MA, de Champlain J. Cyclooxygenase-2 inhibitors attenuate angiotensin II-induced oxidative stress, hypertension, and cardiac hypertrophy in rats. Hypertension 2005; 45: 1139-1144. http://doi: 10.1161/01. HYP.0000164572.92049.29.
Wen Y, Liu Y, Tang T, Lv L, Liu H, Ma K, Liu B. NLRP3 inflammasome activation is involved in Ang II-induced kidney damage via mitochondrial dysfunction. Onco- target 2016;7:54290-54302. http://doi: 10.18632/oncotarget.11091.
Thakur S, Li L, Gupta S. NF-κB-mediated integrin-linked kinase regulation in angiotensin II-induced pro-fibrotic process in cardiac fibroblasts. Life Sci 2014;107:68- 75. http://doi: 10.1016/j.lfs.2014.04.030.
Weber KT, Swamynathan SK, Guntaka RV, Sun Y. Angiotensin II and extracellular matrix homeostasis. J Biochem Cell Biol 1999;31:395-403. http://doi: 10.1016/ s1357-2725(98)00125-3.
Weisinger RS, Begg DP, Chen N, Jois M, Mathai ML, Sinclair AJ. The problem of obesity: is there a role for antagonists of the renin-angiotensin system? Asia Pac J Clin Nutr 2007; 16:359-367.
Maeda A, Tamura K, Wakui H, Dejima T, Ohsawa M, Azushima K, Kanaoka T, Uneda K, Matsuda M, Yamashita A, Miyazak, NK, Hirawa N, Toya Y, Umemura S. Angiotensin receptor-binding protein ATRAP/ Agtrap inhibits metabolic dysfunction with visceral obesity. J Am Heart Assoc 2013;2: e000312. http://doi: 10.1161/ JAHA.113.000312.
Xue B, Thunhorst RL, Yu Y, Guo F, Beltz TG, Felder RB, Johnson AK. Central renin-angiotensin system activation and inflammation induced by high-fat diet sensitize angiotensin II-elicited hypertension. Hypertension. 2016; 67:163-170. http://doi: 10.1161/HYPERTENSIONAHA.115.06263.
Tsuchiya K, Yoshimoto T, Hirono Y, Tateno Tama T, Hirata Y. Angiotensin II induces monocyte chemoattractant protein-1 expression via a nuclear factor-kappaB- dependent pathway in rat preadipocytes. Am J Physiol Endocrinol Metab 2006;291: E771-778. http://doi: 10.1152/ajpen- do.00560.2005.
Menikdiwela KR, Ramalingam L, Allen L, Scoggin S, Kalupahana NS, Moustaid- Moussa N. Angiotensin II increases endoplasmic reticulum stress in adipose tissue and adipocytes. Sci Rep 2019; 9:8481. http://doi: 10.1038/s41598-019-44834-8.
Zhang JX, Lin X, Xu J, Tang F. Hyperuricemia inhibition protects SD rats against fructose-induced obesity hypertension via modulation of inflammation and renin-an-giotensin system in adipose tissue. Exp Clin Endocrinol Diabetes 2021; 129:314-321. http://doi:10.1055/a-1023-6710.
Hussain T. Renal angiotensin II receptors, hyperinsulinemia, and obesity. Clin Exp Hypertens 2003; 25:395-403. http://doi: 10.1081/ceh-120024983.
Chalmers L, Kaskel FJ, Bamgbola O. The role of obesity and its bioclinical correlates in the progression of chronic kidney disease. Adv Chronic Kidney Dis 2006; 13:352-364. http://doi: 10.1053/j. ackd.2006.07.010.
Gao N, Wang H, Zhang X, Yang Z. The inhibitory effect of angiotensin II on BKCa channels in podocytes via oxidative stress. Mol Cell Biochem 2015;398:217-222. http://doi: 10.1007/s11010-014-2221-1.
Saginova EA, Fedorova EIu, Fomin VV, Moiseev SV, Minakova EG, Gitel’ EP, Samokhodskaia LM, Kutyrina IM, Mukhin NA. [Development of renal affection in obese patients]. Ter Arkh 2006; 78:36-41.
Stepp DW, Boesen EI, Sullivan JC, Mintz JD, Hair CD, Pollock DM. Obesity augments vasoconstrictor reactivity to angiotensin II in the renal circulation of the Zucker rat. Am J Physiol Heart Circ Physiol 2007 ;293:H2537-542. http://doi: 10.1152/ajpheart.01081.2006.
Hongo M, Ishizaka N, Furuta K, Yahagi N, Saito K, Sakurai R, Matsuzaki G. Koike K, Nagai R. Administration of angiotensin II, but not catecholamines, induces accumulation of lipids in the rat heart. Eur J Pharmacol 2009; 604:87-92. http://doi: 10.1016/j.ejphar.2008.12.006.
Mayor F Jr, Cruces-Sande M, Arcones AC, Vila-Bedmar R, Briones AM, Salaices M, Murga C. G protein-coupled receptor kinase 2 (GRK2) as an integrative signalling node in the regulation of cardiovascular function and metabolic homeostasis. Cell Signal 2018; 41:25-32. http://doi: 10.1016/j.cellsig.2017.04.002.
Glenn DJ, Cardema MC, Ni W, Zhang Y, Yeghiazarians Y, Grapov D, Fiehn O, Gardner DG. Cardiac steatosis potentiates angiotensin II effects in the heart. Am J Physiol Heart Circ Physiol 2015;308:H339-350. http://doi:10.1152/ajpheart.00742.2014.
Sarzani R, Salvi F, Dessì-Fulgheri P, Rappelli A. Renin-angiotensin system, natriuretic peptides, obesity, metabolic syndrome, and hypertension: an integrated view in humans. J Hypertens 2008; 26:831-843. http://doi: 10.1097/ HJH.0b013e3282f624a0.
du Toit EF, Nabben M, Lochner A. A potential role for angiotensin II in obesity induced cardiac hypertrophy and ischaemic/ reperfusion injury. Basic Res Cardio 2005; 100:346-354. http://doi: 10.1007/s00395-005-0528-5.
Kintscher U, Lyon CJ, Law RE. Angiotensin II, PPAR-gamma and atherosclerosis. Front Biosci 2004; 9:359-369. http://doi: 10.2741/1225.
Schuchard J, Winkler M, Stölting I, Schuster F, Vogt FM, Barkhausen J, Thorns C, Santos RA, Bader M, Raasch W. Lack of weight gain after angiotensin AT1 receptor blockade in diet-induced obesity is partly mediated by an angiotensin-(1-7)/ Mas-dependent pathway. Br J Pharmacol 2015; 172:3764-3778. http://doi: 10.1111/ bph.13172.
Kochueva M, Sukhonos V, Shalimova A, Psareva V, Kirichenko N. State of integral remodeling parameters of target organs in patients with essential hypertension and obesity. Georgian Med News 2014;231:26-30.
South AM, Nixon PA, Chappell MC, Diz DI, Russell GB, Shaltout HA, O’Shea MT, Washburn LK. Obesity is associated with higher blood pressure and higher levels of angiotensin II but lower angiotensin-(1-7) in adolescents born preterm. J Pediatr 2019; 205:55-60. http://doi: 10.1016/j. jpeds.2018.09.058.
Xue B, Yu Y, Zhang Z, Guo F, Beltz TG, Thunhorst RL, Felder RB, Johnson AK. Leptin mediates high-fat diet sensitization of angiotensin II-elicited hypertension by upregulating the brain renin-angiotensin system and inflammation. Hypertension 2016; 67:970-976. http://doi: 10.1161/HY- PERTENSIONAHA.115.06736.
Deji N, Kume S, Araki S, Isshiki K, Araki H, Chin-Kanasaki M, Tanaka Y, Nishiyama A, Koya D, Haneda M, Kashiwagi A, Maegawa H, Uzu T. Role of angiotensin II-mediated AMPK inactivation on obesity-related salt-sensitive hypertension. Biochem Biophys Res Commun 2012; 418:559-564. http://doi:10.1016/j. bbrc.2012.01.070.
Asferg CL, Nielsen SJ, Andersen UB, Linneberg A, Møller DV, Hedley PL, Christiansen M, Goetze JP, Esler M, Jeppesen JL. Relative atrial natriuretic peptide deficiency and inadequate renin and angiotensin II suppression in obese hypertensive men. Hypertension 2013; 62:147-153. http://doi: 10.1161/HYPERTENSIONA-HA.111.00791.
Vaidya A, Forman JP, Williams JS. Vitamin D and the vascular sensitivity to angiotensin II in obese Caucasians with hypertension. J Hum Hypertens 2011; 25:672-678. http://doi: 10.1038/jhh.2010.110.
Lebovitz HE. Insulin resistance: definition and consequences. Exp Clin Endocrinol Diabetes 2001;109:S135-148. http://doi: 10.1055/s-2001-18576.
Olivares-Reyes JA, Arellano-Plancarte A, Castillo-Hernandez JR. Angiotensin II and the development of insulin resistance: implications for diabetes. Mol Cell Endocrinol 2009; 302:128-139. http://doi: 10.1016/j. mce.2008.12.011.
Ohki K, Wakui H, Kishio N, Azushima K, Uneda K , Haku S, Kobayashi R, Haruhara K, Kinguchi S, Yamaji T, Yamada T, Minegishi S, Ishigami T, Toya Y, Yamashita A, Imajo K, Nakajima A, Kato I, Ohashi K, Tamura K. Angiotensin II Type 1 receptor- associated protein inhibits angiotensin II- induced insulin resistance with suppression of oxidative stress in skeletal muscle tissue. Sci Rep 2018; 8:2846. http://doi: 10.1038/ s41598-018-21270-8.
Gao M, Du Y, Xie JW, Xue J, Wang YT, Qin L, Ma MM, Tang YB, Li XY. Redox signal-mediated TRPM2 promotes Ang II- induced adipocyte insulin resistance via Ca 2+-dependent CaMKII/JNK cascade. Metabolism 2018; 85:313-324. http://doi: 10.1016/j.metabol.2018.05.005.
Fuke Y, Fujita T, Satomura A, Wada Y, Matsumoto K. Alterations of insulin resistance and the serum adiponectin level in patients with Type 2 diabetes mellitus under the usual antihypertensive dosage of telmisartan treatment. Diabetes Technol Ther 2010; 12:393-398. http://doi: 10.1089/ dia.2009.0126.
López-Jaramillo P, Gómez-Arbeláez D, López-López J, López-López C, Martínez-Ortega J, Gómez-Rodríguez A, Martínez-Ortega J, Gómez-Rodríguez A, Triana-Cubillos S. The role of leptin/ adiponectin ratio in metabolic syndrome and diabetes. Horm Mol Biol Clin Inves- tig 2014; 18:37-45. http://doi: 10.1515/ hmbci-2013-0053.
Skurk T, van Harmelen V, Blum WF, Hauner H. Angiotensin II promotes leptin production in cultured human fat cells by an ERK1/2-dependent pathway. Obes Res 2005; 13:969-973. http://doi: 10.1038/ oby.2005.113.
Fortuño A, Rodríguez A, Gómez-Ambrosi J, Muñiz P, Salvador J, Díez J, Frühbeck G. Leptin inhibits angiotensin II-induced intracellular calcium increase and vaso-constriction in the rat aorta. Endocrinology 2002; 143:3555-3560. http://doi: 10.1210/ en.2002-220075.
Suzuki H, Eguchi S. Adiponectin versus angiotensin II: Key pathological role of their misbalance. Kidney Int 2006; 70:1678- 1679. http://doi: 10.1038/sj.ki.5001936.
Matsuzawa Y, Funahashi T, Kihara S, Shimomura I. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 2004; 24: 29–33. http://doi: 10.1161/01. ATV.0000099786.99623.EF.
Furuhashi M, Ura N, Higashiura K, Mu- rakami H, Tanaka M, Moniwa N, Yosida D, Shimamoto K. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 2003; 42: 76–81. http://doi: 10.1161/01. HYP.0000078490.59735.6E.
Christou GA, Kiortsis DN. The role of adiponectin in renal physiology and development of albuminuria. J Endocrinol 2014;221: R49-61. http://doi: 10.1530/ JOE-13-0578.
Mutch NJ, Wilson HM, Booth NA. Plasminogen activator inhibitor-1 and haemostasis in obesity. Proc Nutr Soc 2001;6:341- 347. http://doi: 10.1079/pns200199.
Skurk T, Lee YM, Hauner H. Angiotensin II and its metabolites stimulate PAI-1 protein release from human adipocytes in primary
Publicado
2022-11-10
Cómo citar
Mosquera-Sulbarán, J., Ryder, E., Vargas, R., & Pedreáñez, A. (2022). Angiotensin II and human obesity. A narrative review of the pathogenesis.: Angiotensina II y obesidad humana. Revisión narrativa de la patogénesis. Investigación Clínica, 63(4), 435-453. https://doi.org/10.54817/IC.v63n4a09
Sección
Artículos
